A study led by researchers from the Institute Cajal of Spanish Research Council (CSIC) in Madrid, Spain in collaboration with the Bioengineering Department of George Mason University in Virginia, U.S. has updated one of the world’s largest databases on neuronal types, Hippocampome.org. The study, which is published in the journal PLOS Biology, represents the most …

Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced that John E Hart has been named as President and Chief Executive Officer to lead the company. Hart has more than 35 years of executive leadership experience in the medical device, life science and biologics fields serving in general …

The Center for Innovative Technology (CIT), the nonprofit operations arm of the Virginia Innovation Partnership Authority (VIPA), announced that CIT GAP Funds has added two new Investment Associates to its team: Dustin Dunbar and Anthony Obi Jr. As Investment Associates, Dunbar, and Obi will support CIT GAP Funds activity including deal sourcing and due diligence …

KinergyCare is a Virginia-based startup and a Virginia Bio member that is requesting feedback from this community on a care coaching and coordination approach that focuses on the needs of patients with cardiovascular disease. We’re pioneering a new approach that combines patient data on health capabilities with a personalized intervention based on behavioral science. The result should …

Virginia Bio and the Virginia Bioscience Foundation have named Albemarle High School’s, Meenakshi “Meena” Ambati, as the winner of the 2021 Virginia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As the Virginia BioGENEius finalist, Meena will attend the 2021 BIO Digital Conference, where …

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a no objection letter (NOL) from Health Canada to an Amendment of the Company’s Phase 1 clinical trial of RLS-0071 in healthy volunteers. The study design has been modified to add …